You can read our Premium News Service in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.
12 August 2021
Bayer Consumer Health said its North American business had performed “very well” in the second quarter of 2021, thanks to a strong allergy season, continued high demand for Nutritionals and the launch of AleveX.
15 July 2021
Bausch Health Companies has extended its Biotrue eyecare brand in the US, Bayer Consumer Health is backing the launch of AleveX with a golf-themed campaign, and AFT Pharmaceuticals has received regulatory approval for Maxigesic Oral Liquid in two countries.
18 June 2021
The US Food and Drug Administration (FDA) has approved the switch of Astepro (azelastine hydrochloride 0.15%) from prescription-to-OTC status. Bayer said its Astepro Allergy Nasal Spray would be available at national mass retail locations in the first quarter of 2022.
7 June 2021
Bayer has launched a Consumer Health division in India with a focus on 10 leading brands including Saridon pain relievers and Supradyn multivitamins.
14 May 2021
Bayer Consumer Health’s worldwide sales declined in the first quarter of 2021, as sales of the company’s Allergy & Cold products dropped by around 30%.
16 March 2021
Bayer Consumer Health aims to accelerate its growth in fast-growing and profitable markets including the US, China, India and South-East Asia, says Heiko Schipper, president of the division.
4 March 2021
US-based colostrum specialist PanTheryx has acquired the TruBiotics daily probiotic supplement from Bayer for an undisclosed sum.
4 March 2021
Bayer has signed a distribution deal in Egypt, Futura Medical has announced a collaboration in China and South-East Asia, Ipsen has released financial results, and the US Consumer Healthcare Products Association (CHPA) has three new member companies.
1 March 2021
Bayer Consumer Health is strengthening its innovation pipeline and now has more than 110 active projects.
1 March 2021
Bayer Consumer Health’s portfolio of vitamins, minerals and supplements (VMS) continued to record strong sales growth in the fourth quarter of 2020, but sales of the company’s Allergy & Cold products continued to decline.